结直肠癌组织浸润免疫细胞组成及特征

doi:10.3969/j.issn.2095-9400.2020.06.005

Abstract
Figure/Table
References (0)
Related Citation (7)

Download: PDF (1563 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the infiltrated immune cells in colorectal cancer patients and normal people, and to provide new ideas and directions for cancer related research. Methods: Gene expression profiles of 51 normal people and 333 colorectal cancer (CRC) patients from GEO database were analyzed, and CIBERSORT was used to transform the gene expression profile data into the infiltration ratio of 22 kinds of immune cells, and the distribution of these immune cells in both groupd of patients was compared. Results: The composition of intestinal infiltrated immune cells was significantly different between CRC patients and healthy people. The infiltration of T cells and B cells in tumor tissue was less than that in healthy people, while the infiltration of macrophages, neutrophils, mast cells and dendritic cells in tumor tissue was more than that in healthy people. Conclusion: There are great differences in the infiltration of immune cells in colorectal tissues between CRC patients and healthy people. These different immune cells may play an important role in the development of cancer.

Key words： colorectal cancer CIBERSORT tumor microenvironment immune cells

Received: 30 October 2019

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Linfeng
	SUN Yongji
	YE Lele
	SHEN Xian
	XUE Xiangyang
	SHEN Shurong

URL:

https://xb.wmu.edu.cn/EN/10.3969/j.issn.2095-9400.2020.06.005 OR https://xb.wmu.edu.cn/EN/Y2020/V50/I6/454

[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2018, 68(6): 394-424.
[2] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66(2): 115-132.
[3] HANAHAN D, WEINBERG R A. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674.
[4] MIYASHITA M, SASANO H, TAMAKI K, et al. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study[J]. Breast Cancer Res, 2015, 17: 124.
[5] FENG W, LI Y, SHEN L, et al. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer[J]. Oncotarget, 2016, 7(6): 7227-7240.
[6] MAHMOUD S M, PAISH E C, POWE D G, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer[J]. J Clin Oncol, 2011, 29(15): 1949-1955.
[7] JENSEN H K, DONSKOV F, NORDSMARK M, et al. Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma[J]. Clin Cancer Res, 2009, 15(3): 1052-1058.
[8] YANG L, WANG F, WANG L, et al. CD163+ tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients[J]. Oncotarget, 2015, 6(12): 10592-10603.
[9] GALON J, FRIDMAN W H, PAGÈS F. The adaptive immunologic microenvironment in colorectal cancer: a novel per-spective[J]. Cancer Res, 2007, 67(5): 1883-1886.
[10] NEWMAN A M, LIU C L, GREEN M R, et al. Robust enumeration of cell subsets from tissue expression profiles[J]. Nat Methods, 2015, 12(5): 453-457.
[11] DE VISSER K E, EICHTEN A, COUSSENS L M. Paradoxical roles of the immune system during cancer development [J]. Nat Rev Cancer, 2006, 6(1): 24-37.
[12] GRIVENNIKOV S I, GRETEN F R, KARIN M. Immunity, inflammation, and cancer[J]. Cell, 2010, 140(6): 883-899.
[13] PALUCKA A K, COUSSENS L M. The Basis of Oncoim-munology[J]. Cell, 2016, 164(6): 1233-1247.
[14] SCHREIBER R D, OLD L J, SMYTH M J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion[J]. Science, 2011, 331(6024): 1565-1570.
[15] NAITO Y, SAITO K, SHIIBA K, et al. CD8+T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer[J]. Cancer Res, 1998, 58(16): 3491-3494.
[16] DIEDERICHSEN A C, JV H, CHRISTENSEN P B, et al. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells[J]. Cancer Immunol Immunother, 2003, 52(7): 423-428.
[17] BERNTSSON J, NODIN B, EBERHARD J, et al. Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer[J]. Int J Cancer, 2016, 139(5): 1129-1139.
[18] ROHR-UDILOVA N, KLINGLMÜLLER F, SCHULTE-HERMANN R, et al. Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma[J]. Sci Rep, 2018, 8(1): 6220.
[19] JUNTTILA M R , DE SAUVAGE F J. Influence of tumour micro-environment heterogeneity on therapeutic response[J]. Nature, 2013, 501(7467): 346-354.
[20] RUFFELL B, AFFARA N I, COUSSENS L M. Differential macrophage programming in the tumor microenvironment [J]. Trends Immunol, 2012, 33(3): 119-126.
[21] ZHANG Q W, LIU L, GONG C Y, et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature[J]. PLoS One, 2012, 7(12): e50946.
[22] LAN C, HUANG X, LIN S, et al. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer[J]. Technol Cancer Res Treat, 2013, 12(3): 259-267.
[23] ECK M, SCHMAUSSER B, SCHELLER K, et al. Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma[J]. Clin Exp Immunol, 2003, 134(3): 508-515.
[24] TRELLAKIS S, BRUDEREK K, DUMITRU C A, et al. Polymorphonuclear granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease[J]. Int J Cancer, 2011, 129(9): 2183-2193.
[25] JENSEN H K, DONSKOV F, MARCUSSEN N, et al. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma[J]. J Clin Oncol, 2009, 27(28): 4709-4717.
[26] JENSEN T O, SCHMIDT H, MØLLER H J, et al. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma[J]. Cancer, 2012, 118(9): 2476-2485.
[27] LI Y W, QIU S J, FAN J, et al. Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection[J]. J Hepatol, 2011, 54(3): 497-505.
[28] GU F M, GAO Q, SHI G M, et al. Intratumoral IL-17+cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2012, 19(8): 2506-2514.
[29] COFFELT S B, KERSTEN K, DOORNEBAL C W, et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis[J]. Nature, 2015, 522(7556): 345-348.
[30] CARUSO R A, BELLOCCO R, PAGANO M, et al. Prognostic value of intratumoral neutrophils in advanced gastric carcinoma in a high-risk area in northern Italy[J]. Mod Pathol, 2002, 15(8): 831-837.
[31] GALDIERO M R, BIANCHI P, GRIZZI F, et al. Occurrence and significance of tumor-associated neutrophils in patients with colorectal cancer[J]. Int J Cancer, 2016, 139(2): 446-456.
[32] WIKBERG M L, LING A, LI X,et al. Neutrophil infiltration is a favorable prognostic factor in early stages of colon cancer[J]. Hum Pathol, 2017, 68: 193-202.
[33] OLDFORD S A, MARSHALL J S. Mast cells as targets for immunotherapy of solid tumors[J]. Mol Immunol, 2015, 63(1): 113-124.
[34] JENSEN-JAROLIM E, ACHATZ G, TURNER M C, et al. AllergoOncology: the role of IgE-mediated allergy in cancer [J]. Allergy, 2008, 63(10): 1255-1266.
[35] BENYON R C, BISSONNETTE E Y, BEFUS A D. Tumor necrosis factor-alpha dependent cytotoxicity of human skin mast cells is enhanced by anti-IgE antibodies[J]. J Immunol, 1991, 147(7): 2253-2258.
[36] SINGER J, JENSEN-JAROLIM E. IgE-based Immunotherapy of Cancer-A Comparative Oncology Approach[J]. J Carcinog Mutagen, 2014, 5(3): 1000176.